Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study

Respir Med. 2024 May:226:107608. doi: 10.1016/j.rmed.2024.107608. Epub 2024 Apr 4.

Abstract

Background: Clinical presentation and prevalence of organ involvement is highly variable in sarcoidosis and depends on ethnic, genetic and geographical factors. These data are not extensively studied in a Dutch population.

Aim: To determine the prevalence of organ involvement and the indication for systemic immunosuppressive therapy in newly diagnosed sarcoidosis patients in the Netherlands.

Methods: Two large Dutch teaching hospitals participated in this prospective cohort study. All adult patients with newly diagnosed sarcoidosis were prospectively included and a standardized work-up was performed. Organ involvement was defined using the WASOG instrument.

Results: Between 2015 and 2020, a total of 330 patients were included, 55% were male, mean age was 46 (SD 14) years. Most of them were white (76%). Pulmonary involvement including thoracic lymph node enlargement was present in 316 patients (96%). Pulmonary parenchymal disease was present in 156 patients (47%). Ten patients (3%) had radiological signs of pulmonary fibrosis. Cutaneous sarcoidosis was present in 74 patients (23%). Routine ophthalmological screening revealed uveitis in 29 patients (12%, n = 256)). Cardiac and neurosarcoidosis were diagnosed in respectively five (2%) and six patients (2%). Renal involvement was observed in 11 (3%) patients. Hypercalcaemia and hypercalciuria were observed in 29 (10%) and 48 (26%, n = 182) patients, respectively. Hepatic involvement was found in 6 patients (2%). In 30% of the patients, systemic immunosuppressive treatment was started at diagnosis.

Conclusions: High-risk organ involvement in sarcoidosis is uncommon at diagnosis. Indication for systemic immunosuppressive therapy was present in a minority of patients.

Keywords: Clinical presentation; Diagnosis; Organ involvement; Organ screening; Sarcoidosis; Treatment indication.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Cardiomyopathies / diagnosis
  • Cardiomyopathies / epidemiology
  • Central Nervous System Diseases / epidemiology
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Diseases / diagnosis
  • Kidney Diseases / epidemiology
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Prevalence
  • Prospective Studies
  • Pulmonary Fibrosis / epidemiology
  • Sarcoidosis* / complications
  • Sarcoidosis* / diagnosis
  • Sarcoidosis* / drug therapy
  • Sarcoidosis* / epidemiology
  • Sarcoidosis, Pulmonary / diagnosis
  • Sarcoidosis, Pulmonary / drug therapy
  • Sarcoidosis, Pulmonary / epidemiology
  • Uveitis* / diagnosis
  • Uveitis* / drug therapy
  • Uveitis* / epidemiology

Substances

  • Immunosuppressive Agents

Supplementary concepts

  • Neurosarcoidosis